Home
Development Programs
For Investors
News
About Us
- Our Name & Brandmark
- Team
Contact

Menu

Home
Development Programs
For Investors
News
About Us
- Our Name & Brandmark
- Team
Contact

Multiple Medical Conditions

Jun 26, 2022

EMD-RX7

OTHERS IN DEVELOPMENT

Jun 25, 2022

OTHERS IN DEVELOPMENT

Search

Search for:

Blogs
General News
In the Media
Information
Investor Updates
Publications

Tag Cloud

anxiety bioavailability blog CBD clinical research dr alistair vickery drug development EMD EMD-RX5 emd-rx7 emyria investor mdma mdma analogue program medicinal cannabis medicinal CBD treatments national institutes for health news NINDS opioid over the counter pain. preclinical psychological conditions psychological distress screening results ultra-pure CBD webinar

Have Questions?

If you have any question, please feel free to get in touch with us.

DEVELOPMENT PROGRAMS

Ultra-Pure CBD Medicines
MDMA-inspired Medicines
Research & Data Programs

Menu

Ultra-Pure CBD Medicines
MDMA-inspired Medicines
Research & Data Programs

FOR INVESTORS

Stock Information
ASX Announcements
Presentations & Videos
Reports & Updates
Corporate Governance

Menu

Stock Information
ASX Announcements
Presentations & Videos
Reports & Updates
Corporate Governance

RECENT TWEETS

#EMD experts share their thoughts on today's TGA decision rescheduling MDMA and psilocybin - see the 7 News story that aired tonight!

© 2023 Emyria Limited

Terms | Privacy | Website by Glide

Phone
08 6559 2800

Email
info@emyria.com

Linkedin Twitter Youtube

First Name*
Last Name*
Email*
Post code
What news are you interested in?*
- Clinical news
- Patient news
- Investor news
- Partners news
CAPTCHA
Email
This field is for validation purposes and should be left unchanged.

Δ

Search for:

Hit enter to search or ESC to close

Home
Development Programs
For Investors
News
About Us
- Our Name & Brandmark
- Team
Contact

Call 08 6559 2800 Contact